Adherence to Triple Single-Pill Combination of Perindopril/Indapamide/Amlodipine: Findings from Real-World Analysis in Italy.


Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
04 2023
Historique:
received: 30 11 2022
accepted: 01 02 2023
medline: 5 4 2023
pubmed: 25 2 2023
entrez: 24 2 2023
Statut: ppublish

Résumé

Single-pill combination therapy for hypertension is recognized to improve adherence to treatment. However, less is known about the benefits of triple single-pill combinations. This retrospective observational analysis aimed to assess changes in adherence when treatment was switched from perindopril (PER)/indapamide (IND) + amlodipine (AML) to PER/IND/AML single-pill combination, in Italian clinical practice. This analysis used data extracted from administrative databases of Italian healthcare entities. Adult patients receiving PER/IND/AML were selected, and the prescription date was considered as the index date. Among them, those who had a prescription for PER/IND + AML during the 12 months before the index date and a prescription of PER/IND/AML during 6 months of follow-up were included. Adherence was calculated as the proportion of days covered (PDC: PDC < 40%, non-adherent; PDC = 40-79%, partially adherent; PDC ≥ 80%, adherent). Among the identified patients, 158 were exposed users and were included in the analysis. When patients were compared before and after switch to triple single-pill combination, the proportion of adherent patients was significantly higher with PER/IND/AML single-pill combination (75.3%) than with PER/IND + AML combination (44.3%) (P < 0.05). Conversely, the proportion of non-adherent patients was lower with the PER/IND/AML single-pill combination (14.6%) vs PER/IND + AML (17.7%) (P < 0.001). This real-world analysis showed that switching to a triple single-pill combination could offer an opportunity to improve adherence to antihypertensive treatment in real-life clinical practice. Medication adherence is defined by the World Health Organization as the “extent to which a person’s behavior (in taking medication) corresponds with agreed recommendations from a healthcare provider”. Low levels of medication adherence in hypertension have been linked with increased disease burden and with higher costs for patients. Patients with hypertension whose blood pressure is poorly controlled often need to receive more than one pill. Nevertheless, having to take many pills may result in poor adherence, i.e., patients not taking their treatment as prescribed. Combining multiple drugs into a single pill for the management of hypertension is known to improve adherence; however, limited evidence exists about the benefits of triple single-pill combinations compared with equivalent free combinations in real clinical practice. This analysis evaluated changes in adherence before and after patients switched from a three-drug therapy of perindopril/indapamide single-pill + amlodipine (PER/IND + AML) to perindopril/indapamide/amlodipine (PER/IND/AML) taken as a single pill. In this analysis, real-world data from Italian administrative databases covering around 11% of the Italian population were used. Overall, 158 patients were included. More patients were found to be adherent after switch to PER/IND/AML single pill (75.3% vs 44.3% of PER/IND + AML combination). Partially adherent and poorly adherent patients were fewer with PER/IND/AML single-pill combination (10.1% and 14.6%, respectively) compared to PER/IND + AML combination (38.0% and 17.7%, respectively). These findings indicate that switching to a simplified therapy in which all three drugs are taken in one pill may offer an opportunity for increasing the number of patients that are adherent to their medication.

Autres résumés

Type: plain-language-summary (eng)
Medication adherence is defined by the World Health Organization as the “extent to which a person’s behavior (in taking medication) corresponds with agreed recommendations from a healthcare provider”. Low levels of medication adherence in hypertension have been linked with increased disease burden and with higher costs for patients. Patients with hypertension whose blood pressure is poorly controlled often need to receive more than one pill. Nevertheless, having to take many pills may result in poor adherence, i.e., patients not taking their treatment as prescribed. Combining multiple drugs into a single pill for the management of hypertension is known to improve adherence; however, limited evidence exists about the benefits of triple single-pill combinations compared with equivalent free combinations in real clinical practice. This analysis evaluated changes in adherence before and after patients switched from a three-drug therapy of perindopril/indapamide single-pill + amlodipine (PER/IND + AML) to perindopril/indapamide/amlodipine (PER/IND/AML) taken as a single pill. In this analysis, real-world data from Italian administrative databases covering around 11% of the Italian population were used. Overall, 158 patients were included. More patients were found to be adherent after switch to PER/IND/AML single pill (75.3% vs 44.3% of PER/IND + AML combination). Partially adherent and poorly adherent patients were fewer with PER/IND/AML single-pill combination (10.1% and 14.6%, respectively) compared to PER/IND + AML combination (38.0% and 17.7%, respectively). These findings indicate that switching to a simplified therapy in which all three drugs are taken in one pill may offer an opportunity for increasing the number of patients that are adherent to their medication.

Identifiants

pubmed: 36829102
doi: 10.1007/s12325-023-02451-y
pii: 10.1007/s12325-023-02451-y
pmc: PMC10070199
doi:

Substances chimiques

Amlodipine 1J444QC288
Perindopril Y5GMK36KGY
Indapamide F089I0511L
Antihypertensive Agents 0
Drug Combinations 0

Types de publication

Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1765-1772

Informations de copyright

© 2023. The Author(s).

Références

Borghi C, Desideri G, Tocci G, Trimarco B, Nati G. Aderenza alla terapia delle malattie cardiovascolari croniche: nuove soluzioni. G Ital Cardiol. 2021;22(5 Suppl 1):e86–91.
Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692–705.
doi: 10.1161/HYPERTENSIONAHA.120.15781 pubmed: 33390044
Weisser B, Predel HG, Gillessen A, et al. Single pill regimen leads to better adherence and clinical outcome in daily practice in patients suffering from hypertension and/or dyslipidemia: results of a meta-analysis. High Blood Press Cardiovasc Prev. 2020;27:157–64.
doi: 10.1007/s40292-020-00370-5 pubmed: 32219670 pmcid: 7160084
Degli Esposti L, Perrone V, Veronesi C, et al. Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (AMPERES) study. Curr Med Res Opin. 2018;34:1571–7.
Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11–21.
doi: 10.1097/MLR.0b013e31829b1d2a pubmed: 23774515 pmcid: 3727405
Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.
doi: 10.1136/bmj.39553.670231.25 pubmed: 18480115 pmcid: 2386633
Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124–40.
doi: 10.1161/CIRCRESAHA.118.313220 pubmed: 30920917
Gupta P, Patel P, Štrauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69(6):1113–20.
doi: 10.1161/HYPERTENSIONAHA.116.08729 pubmed: 28461599
Corrao G, Mancia G. Research strategies in treatment of hypertension: value of retrospective real-life data. Eur Heart J. 2022;43(35):3312–22.
doi: 10.1093/eurheartj/ehab899 pubmed: 35134885
World Health Organization. Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines: WHO Headquarters, Geneva, 1–5 April 2019. World Health Organization. 2019. https://apps.who.int/iris/handle/10665/325773 .
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.
doi: 10.1093/eurheartj/ehy339 pubmed: 30165516
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004.
doi: 10.1097/HJH.0000000000002453 pubmed: 32371787
Markovitz AA, Mack JA, Nallamothu BK, Ayanian JZ, Ryan AM. Incremental effects of antihypertensive drugs: instrumental variable analysis. BMJ. 2017;359:j5542.
doi: 10.1136/bmj.j5542 pubmed: 29273586 pmcid: 5736968
Paczkowska-Walendowska M, Sip S, Staszewski R, Cielecka-Piontek J. Single-pill combination to improve hypertension treatment: pharmaceutical industry development. Int J Environ Res Public Health. 2022;19:4156.
doi: 10.3390/ijerph19074156 pubmed: 35409840 pmcid: 8999086
Ábrahám G, Dézsi CA. The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine: the results of the PETRA study. Adv Ther. 2017;34(7):1753–63.
doi: 10.1007/s12325-017-0572-1 pubmed: 28646394
Tsioufis K, Douma S, Kallistratos MS, Manolis AJ. Effectiveness and adherence to treatment with perindopril/indapamide/amlodipine single-pill combination in a Greek population with hypertension. Clin Drug Investig. 2019;39(4):385–93.
doi: 10.1007/s40261-019-00761-0 pubmed: 30790132

Auteurs

Claudio Borghi (C)

University of Bologna, IRCCS Ospedale S. Orsola, Bologna, Italy. claudio.borghi@unibo.it.

Pathiyil Balagopalan Jayagopal (PB)

Lakshmi Hospital, Palakkad, India.

Alexandra Konradi (A)

Almazov National Medical Research Center, St. Petersburg, Russian Federation.

Luiz Aparecido Bortolotto (LA)

Instituto do Coração, Hospital das Clinicas-FMUSP, Sao Paolo, Brazil.

Luca Degli Esposti (L)

CliCon S.r.l, Società Benefit-Health, Economics and Outcomes Research, Bologna, Italy.

Valentina Perrone (V)

CliCon S.r.l, Società Benefit-Health, Economics and Outcomes Research, Bologna, Italy.

Jacques R Snyman (JR)

Forte Research (Pty Ltd) and Private Practice, Pretoria, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH